AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 242 min read$ZYME

Zymeworks Inc. (ZYME) Posts Phase 1 ZW191 Data Showing High Responses, Better Tolerability at 6.4 mg/kg

Zymeworks Inc. (ZYME) reported Phase 1 data for ZW191, showing 64.5% objective response rate at 6.4 mg/kg in platinum-resistant ovarian cancer. The treatment demonstrated favorable tolerability and activity across FRα expression levels. A conference call is scheduled for October 27.

Original reporting
tradingview.com
Published Oct 24, 2026, 6:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 24, 2026, 6:38 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Zymeworks Inc. (ZYME) Posts Phase 1 ZW191 Data Showing High Responses, Better Tolerability at 6.4 mg/kg — source image
Source · tradingview.com
Decision brief

The 30-second read

$ZYMEBullishMed
01

Why it matters

The data provides a clear dose‑selection signal and may accelerate partnership talks, influencing the stock price.

02

Market read

New trial data is a material catalyst for Zymeworks and could affect related ADC stocks.

03

What to watch

Future dosing strategy and regulatory pathway remain uncertain; partnership terms will drive valuation.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Zymeworks released its first‑in‑human Phase 1 results for ADC ZW191 targeting folate‑receptor alpha in heavily pretreated, platinum‑resistant ovarian cancer patients.

Company-level read

Ticker impact

$ZYMEBullishHigh confidence
Context

Phase 1 data shows 64.5% cORR at 6.4 mg/kg in platinum‑resistant ovarian cancer, with lower grade ≥3 AEs versus higher dose.

Expected impact

likely upside as investors price in favorable trial results and potential partnership upside

Evidence & confidence

Phase 1 data is a primary disclosure for a biotech; high response rates and better safety are material catalysts.

Market effects

Sector

May boost sentiment for ADC and ovarian‑cancer biotech peers.

Regional

North American biotech sector could see modest gains.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

Phase 1 data may be early; efficacy could wane in later trials, so caution is warranted.

Key entities

  • company
    Zymeworks Inc.

    Biotech developing antibody‑drug conjugates, ticker ZYME.

Read at source← All news

StoryZymeworks reports Phase 1 data for ZW191 showing high response rates and better tolerability at 6.4 mg/kg

Also covered by

4 outlets

Related articles

OCT 24
$ZYMEMedAI 8/10

Zymeworks Inc.: Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

Zymeworks Inc. (ZYME) presented Phase 1 data for ZW191, a folate receptor alpha-targeting antibody-drug conjugate, at ESMO Congress 2026. The study showed a 64.5% objective response rate in high-grade serous platinum-resistant ovarian cancer patients at the 6.4 mg/kg dose, with a favorable tolerability profile. The company plans to continue clinical development and is exploring strategic partnerships. A conference call is scheduled for October 27, 2026.

finanznachrichten.de2 min
OCT 24
$ZYMEMedAI 8/10

Zymeworks reports trial results for ovarian cancer drug ZW191

Zymeworks Inc. (NASDAQ:ZYME) presented Phase 1 trial results for ZW191, an ovarian cancer drug, at the ESMO Congress 2026. The study involved 80 patients with platinum-resistant ovarian cancer, showing response rates of 64.5% and 55.3% at 6.4 mg/kg and 9.6 mg/kg doses, respectively. The company is exploring strategic partnerships for the drug.

investing.com2 min
OCT 24
$ZYMEMedAI 8/10

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

Zymeworks Inc. (ZYME) presented Phase 1 data for ZW191, an antibody-drug conjugate, at ESMO Congress 2026. ZW191 showed a 64.5% objective response rate in high-grade serous platinum-resistant ovarian cancer patients at 6.4 mg/kg. The median duration of response was not yet reached, with a 61% six-month progression-free survival rate. Zymeworks plans to continue clinical development and explore strategic collaborations.

thewhig.com2 min
OCT 24
$ZYMEMedAI 9/10

An experimental ovarian cancer drug showed responses in 55% of patients whose tumors had little or no target protein.

Zymeworks Inc. (ZYME) presented clinical data for ZW191, an ovarian cancer drug, at ESMO 2026. The study showed a 64.5% response rate in high-grade serous platinum-resistant ovarian cancer patients at the 6.4 mg/kg dose, with a six-month progression-free survival rate of 61%. The company plans to discuss the results in a conference call on October 27, 2026.

stocktitan.net2 min
OCT 23
$ZYMEHighAI 8/10

Jefferies raises Zymeworks stock price target on Roche deal

Jefferies raised its price target on Zymeworks (NASDAQ:ZYME) to $52 from $50, maintaining a Buy rating after its licensing deal with Roche. The deal includes $55M upfront, $40M upon Phase 1b trial initiation, and up to $718M in milestone payments. Zymeworks' stock is currently at $28.30, up 63% over the past year. The company also completed its acquisition of Theravance Biopharma, which could generate over $100M in annual cash flow.

investing.com2 min
OCT 23
$ZYMEHighAI 8/10

Roche Bets $55 Million Upfront on Zymeworks' Trispecific in Bid to Outdo Amgen's Imdelltra — BigGo Finance

Roche will pay Zymeworks $55M upfront for global rights to ZW209, a trispecific T-cell engager targeting small cell lung cancer, with potential total payments of $813M. Zymeworks' shares rose 5.5% premarket. Roche will fund Phase 1a trials, taking over development and commercialization. ZW209 aims to improve on Amgen's Imdelltra, targeting DLL3, CD3, and CD28. The deal is subject to regulatory approvals.

finance.biggo.com2 min